FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2583998975> ?p ?o ?g. }

• W2583998975 endingPage "3801" @default.
• W2583998975 startingPage "3794" @default.
• W2583998975 abstract "Abstract Purpose: Recent progress in understanding the molecular biology of epithelial ovarian cancer has not yet translated into individualized treatment for these women or improvements in their disease outcome. Gene expression has been utilized to identify distinct molecular subtypes, but there have been no reports investigating whether or not molecular subtyping is predictive of response to bevacizumab in ovarian cancer. Experimental Design: DASL gene expression arrays were performed on FFPE tissue from patients enrolled on the ICON7 trial. Patients were stratified into four TCGA molecular subtypes. Associations between molecular subtype and the efficacy of randomly assigned therapy with bevacizumab were assessed. Results: Molecular subtypes were assigned as follows: 122 immunoreactive (34%), 96 proliferative (27%), 73 differentiated (20%), and 68 mesenchymal (19%). In univariate analysis patients with tumors of proliferative subtype obtained the greatest benefit from bevacizumab with a median PFS improvement of 10.1 months [HR, 0.55 (95% CI, 0.34–0.90), P = 0.016]. For the mesenchymal subtype, bevacizumab conferred a nonsignificant improvement in PFS of 8.2 months [HR 0.78 (95% CI, 0.44–1.40), P = 0.41]. Bevacizumab conferred modest improvements in PFS for patients with immunoreactive subtype (3.8 months; P = 0.08) or differentiated subtype (3.7 months; P = 0.61). Multivariate analysis demonstrated significant PFS improvement in proliferative subtype patients only [HR, 0.45 (95% CI, 0.27–0.74), P = 0.0015]. Conclusions: Ovarian carcinoma molecular subtypes with the poorest survival (proliferative and mesenchymal) derive a comparably greater benefit from treatment that includes bevacizumab. Validation of our findings in an independent cohort could enable the use of bevacizumab for those patients most likely to benefit, thereby reducing side effects and healthcare cost. Clin Cancer Res; 23(14); 3794–801. ©2017 AACR." @default.
• W2583998975 created "2017-02-10" @default.
• W2583998975 creator A5001092701 @default.
• W2583998975 creator A5005798440 @default.
• W2583998975 creator A5008727204 @default.
• W2583998975 creator A5009825394 @default.
• W2583998975 creator A5011351366 @default.
• W2583998975 creator A5013038112 @default.
• W2583998975 creator A5014097745 @default.
• W2583998975 creator A5014184022 @default.
• W2583998975 creator A5019858433 @default.
• W2583998975 creator A5022527560 @default.
• W2583998975 creator A5023292570 @default.
• W2583998975 creator A5026648066 @default.
• W2583998975 creator A5027988619 @default.
• W2583998975 creator A5028513237 @default.
• W2583998975 creator A5028895212 @default.
• W2583998975 creator A5037650974 @default.
• W2583998975 creator A5040495870 @default.
• W2583998975 creator A5047509474 @default.
• W2583998975 creator A5047695952 @default.
• W2583998975 creator A5053919588 @default.
• W2583998975 creator A5056412323 @default.
• W2583998975 creator A5062837404 @default.
• W2583998975 creator A5063215428 @default.
• W2583998975 creator A5066146057 @default.
• W2583998975 creator A5068044534 @default.
• W2583998975 creator A5069976109 @default.
• W2583998975 creator A5091001750 @default.
• W2583998975 date "2017-07-13" @default.
• W2583998975 modified "2023-10-11" @default.
• W2583998975 title "Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes" @default.
• W2583998975 cites W1988141621 @default.
• W2583998975 cites W1988197673 @default.
• W2583998975 cites W2007259088 @default.
• W2583998975 cites W2010234254 @default.
• W2583998975 cites W2068343048 @default.
• W2583998975 cites W2068675926 @default.
• W2583998975 cites W2069537317 @default.
• W2583998975 cites W2107665951 @default.
• W2583998975 cites W2113122060 @default.
• W2583998975 cites W2123696077 @default.
• W2583998975 cites W2124736921 @default.
• W2583998975 cites W2131593373 @default.
• W2583998975 cites W2132619562 @default.
• W2583998975 cites W2135947389 @default.
• W2583998975 cites W2138644182 @default.
• W2583998975 cites W2144487043 @default.
• W2583998975 cites W2146014169 @default.
• W2583998975 cites W2146878122 @default.
• W2583998975 cites W2150291618 @default.
• W2583998975 cites W2160953558 @default.
• W2583998975 cites W2170552969 @default.
• W2583998975 cites W2303726569 @default.
• W2583998975 cites W2313664182 @default.
• W2583998975 cites W2339963131 @default.
• W2583998975 doi "https://doi.org/10.1158/1078-0432.ccr-16-2196" @default.
• W2583998975 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5661884" @default.
• W2583998975 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28159814" @default.
• W2583998975 hasPublicationYear "2017" @default.
• W2583998975 type Work @default.
• W2583998975 sameAs 2583998975 @default.
• W2583998975 citedByCount "90" @default.
• W2583998975 countsByYear W25839989752017 @default.
• W2583998975 countsByYear W25839989752018 @default.
• W2583998975 countsByYear W25839989752019 @default.
• W2583998975 countsByYear W25839989752020 @default.
• W2583998975 countsByYear W25839989752021 @default.
• W2583998975 countsByYear W25839989752022 @default.
• W2583998975 countsByYear W25839989752023 @default.
• W2583998975 crossrefType "journal-article" @default.
• W2583998975 hasAuthorship W2583998975A5001092701 @default.
• W2583998975 hasAuthorship W2583998975A5005798440 @default.
• W2583998975 hasAuthorship W2583998975A5008727204 @default.
• W2583998975 hasAuthorship W2583998975A5009825394 @default.
• W2583998975 hasAuthorship W2583998975A5011351366 @default.
• W2583998975 hasAuthorship W2583998975A5013038112 @default.
• W2583998975 hasAuthorship W2583998975A5014097745 @default.
• W2583998975 hasAuthorship W2583998975A5014184022 @default.
• W2583998975 hasAuthorship W2583998975A5019858433 @default.
• W2583998975 hasAuthorship W2583998975A5022527560 @default.
• W2583998975 hasAuthorship W2583998975A5023292570 @default.
• W2583998975 hasAuthorship W2583998975A5026648066 @default.
• W2583998975 hasAuthorship W2583998975A5027988619 @default.
• W2583998975 hasAuthorship W2583998975A5028513237 @default.
• W2583998975 hasAuthorship W2583998975A5028895212 @default.
• W2583998975 hasAuthorship W2583998975A5037650974 @default.
• W2583998975 hasAuthorship W2583998975A5040495870 @default.
• W2583998975 hasAuthorship W2583998975A5047509474 @default.
• W2583998975 hasAuthorship W2583998975A5047695952 @default.
• W2583998975 hasAuthorship W2583998975A5053919588 @default.
• W2583998975 hasAuthorship W2583998975A5056412323 @default.
• W2583998975 hasAuthorship W2583998975A5062837404 @default.
• W2583998975 hasAuthorship W2583998975A5063215428 @default.
• W2583998975 hasAuthorship W2583998975A5066146057 @default.
• W2583998975 hasAuthorship W2583998975A5068044534 @default.
• W2583998975 hasAuthorship W2583998975A5069976109 @default.
• W2583998975 hasAuthorship W2583998975A5091001750 @default.

• next